On Monday, CytomX Therapeutics Inc (NASDAQ: CTMX) was 4.17% up from the session before settling in for the closing price of $1.20. A 52-week range for CTMX has been $1.04 – $5.85.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 28.25% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at -3053.00%. With a float of $76.79 million, this company’s outstanding shares have now reached $78.12 million.
In an organization with 122 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 97.63%, operating margin of 4.79%, and the pretax margin is 12.61%.
CytomX Therapeutics Inc (CTMX) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward CytomX Therapeutics Inc stocks. The insider ownership of CytomX Therapeutics Inc is 1.70%, while institutional ownership is 72.25%. The most recent insider transaction that took place on Aug 20 ’24, was worth 5,139. In this transaction Chief Business Officer of this company sold 4,181 shares at a rate of $1.23, taking the stock ownership to the 119,056 shares. Before that another transaction happened on Aug 20 ’24, when Company’s SVP, Chief Scientific Officer sold 4,181 for $1.23, making the entire transaction worth $5,139. This insider now owns 175,648 shares in total.
CytomX Therapeutics Inc (CTMX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -3053.00% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.90% during the next five years compared to 67.21% growth over the previous five years of trading.
CytomX Therapeutics Inc (NASDAQ: CTMX) Trading Performance Indicators
You can see what CytomX Therapeutics Inc (CTMX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.00. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.82.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.14, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.61 in one year’s time.
Technical Analysis of CytomX Therapeutics Inc (CTMX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.77 million. That was inferior than the volume of 3.01 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 62.43%. Additionally, its Average True Range was 0.08.
During the past 100 days, CytomX Therapeutics Inc’s (CTMX) raw stochastic average was set at 3.36%, which indicates a significant decrease from 76.19% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.52% in the past 14 days, which was lower than the 223.34% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2870, while its 200-day Moving Average is $1.6969. However, in the short run, CytomX Therapeutics Inc’s stock first resistance to watch stands at $1.3000. Second resistance stands at $1.3500. The third major resistance level sits at $1.4000. If the price goes on to break the first support level at $1.2000, it is likely to go to the next support level at $1.1500. Assuming the price breaks the second support level, the third support level stands at $1.1000.
CytomX Therapeutics Inc (NASDAQ: CTMX) Key Stats
There are 77,919K outstanding shares of the company, which has a market capitalization of 97.65 million. As of now, sales total 101,210 K while income totals -570 K. Its latest quarter income was 25,120 K while its last quarter net income were -6,530 K.
